fbpx

Help more Canadians get protected against shingles

Share on facebook
Share on twitter
Share on linkedin
Share on email

A new study is seeking to understand what is preventing Canadians from getting vaccinated against shingles with Shingrix, which provides the best possible protection. Shingles can cause serious health outcomes including brain damage, hearing loss and balance problems.

We’ve been hearing that many adults are being left vulnerable to this debilitating disease because they only received 1 of the 2 required doses, or got the 2nd dose either too early or too late after getting the 1st dose. Researchers want to understand what is preventing patients from getting both doses on the required schedule.

Help address this important problem by participating in this study and sharing your experience.

QualityMetric, a health research company, is seeking adults, age 50+, who received Shingrix, the 2-dose shingles vaccine, between September 2018 and February 2020 to participate in a 1-hour interview for a research study.

Specifically, the research team is interested in speaking with anyone who:

  • Received ONLY the first dose of Shingrix
  • Received their second dose less than 2 months or more than 6 months after the first one

There is no treatment involved in this study and you will receive $255 for your time.

Interested? Contact chad.miller@qual-world.com for more details.

Related

Canada’s National Seniors’ Advocacy Organization

Factor-Inwentash Faculty of Social Work
University of Toronto

Join CanAge for FREE

®2020 CanAge Inc. All Rights Reserved

You're Registered

Thank you for registering! Details will be emailed to you as soon as possible.

You're Registered

Check your email for more details. Thank you for signing up. We look forward to seeing you soon!

Thank You

By becoming a CanAge member, you’re adding your voice to our calls for change in protecting and improving the lives of older Canadians.

Know someone else who might like to join ?

share this with a friend

Share on facebook
Share on twitter
Share on linkedin
Share on email
Skip to content